Literature DB >> 33717086

The Role of the Immune Response in the Development of Medication-Related Osteonecrosis of the Jaw.

Weidong Zhang1,2, Ling Gao1,3, Wenhao Ren1, Shaoming Li1, Jingjing Zheng3,4, Shasha Li5, Chunmiao Jiang6, Shuying Yang7, Keqian Zhi1,3.   

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug effect. There are multiple hypotheses to explain the development of MRONJ. Reduced bone remodeling and infection or inflammation are considered central to the pathogenesis of MRONJ. In recent years, increasing evidence has shown that bisphosphonates (BPs)-mediated immunity dysfunction is associated with the pathophysiology of MRONJ. In a healthy state, mucosal immunity provides the first line of protection against pathogens and oral mucosal immune cells defense against potentially invading pathogens by mediating the generation of protective immunoinflammatory responses. In addition, the immune system takes part in the process of bone remodeling and tissue repair. However, the treatment of BPs disturbs the mucosal and osteo immune homeostasis and thus impairs the body's ability to resist infection and repair from injury, thereby adding to the development of MRONJ. Here, we present the current knowledge about immunity dysfunction to shed light on the role of local immune disorder in the development of MRONJ.
Copyright © 2021 Zhang, Gao, Ren, Li, Zheng, Li, Jiang, Yang and Zhi.

Entities:  

Keywords:  bisphosphonates; immunity; inflammation; jaw; osteonecrosis

Mesh:

Substances:

Year:  2021        PMID: 33717086      PMCID: PMC7947359          DOI: 10.3389/fimmu.2021.606043

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  117 in total

Review 1.  TLRs/NLRs: Shaping the landscape of host immunity.

Authors:  Komal Dolasia; Manoj K Bisht; Gourango Pradhan; Atul Udgata; Sangita Mukhopadhyay
Journal:  Int Rev Immunol       Date:  2017-12-01       Impact factor: 5.311

2.  Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients.

Authors:  Yehuda Zadik
Journal:  Oral Oncol       Date:  2018-07-29       Impact factor: 5.337

3.  It May Seem Inflammatory, but Some T Cells Are Innately Healing to the Bone.

Authors:  Shirin Kalyan
Journal:  J Bone Miner Res       Date:  2016-06-13       Impact factor: 6.741

Review 4.  Macrophages: Their Emerging Roles in Bone.

Authors:  Benjamin P Sinder; Allison R Pettit; Laurie K McCauley
Journal:  J Bone Miner Res       Date:  2015-12       Impact factor: 6.741

5.  The effect of bisphosphonate therapy on neutrophil function: a potential biomarker.

Authors:  C L Favot; C Forster; M Glogauer
Journal:  Int J Oral Maxillofac Surg       Date:  2013-02-08       Impact factor: 2.789

6.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

7.  Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB.

Authors:  Si-Yong Gao; Guang-Sen Zheng; Lin Wang; Yu-Jie Liang; Si-En Zhang; Xiao-Mei Lao; Kan Li; Gui-Qing Liao
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

Review 8.  Oral microbiomes: more and more importance in oral cavity and whole body.

Authors:  Lu Gao; Tiansong Xu; Gang Huang; Song Jiang; Yan Gu; Feng Chen
Journal:  Protein Cell       Date:  2018-05-07       Impact factor: 14.870

9.  TNF-α Directly Enhances Osteocyte RANKL Expression and Promotes Osteoclast Formation.

Authors:  Aseel Marahleh; Hideki Kitaura; Fumitoshi Ohori; Akiko Kishikawa; Saika Ogawa; Wei-Ren Shen; Jiawei Qi; Takahiro Noguchi; Yasuhiko Nara; Itaru Mizoguchi
Journal:  Front Immunol       Date:  2019-12-13       Impact factor: 7.561

10.  Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.

Authors:  Anke J Roelofs; Marjo Jauhiainen; Hannu Mönkkönen; Michael J Rogers; Jukka Mönkkönen; Keith Thompson
Journal:  Br J Haematol       Date:  2008-11-07       Impact factor: 6.998

View more
  5 in total

1.  Aseptic osteonecrosis of the maxilla after severe COVID-19 infection and its treatment.

Authors:  N Slavkova; M Nedevska
Journal:  Radiol Case Rep       Date:  2022-07-02

Review 2.  The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists.

Authors:  Rodolfo Mauceri; Rita Coniglio; Antonia Abbinante; Paola Carcieri; Domenico Tomassi; Vera Panzarella; Olga Di Fede; Francesco Bertoldo; Vittorio Fusco; Alberto Bedogni; Giuseppina Campisi
Journal:  Support Care Cancer       Date:  2022-03-16       Impact factor: 3.359

3.  Non-Interventional Prospective Observational Study of Platelet Rich Fibrin as a Therapy Adjunctive in Patients with Medication-Related Osteonecrosis of the Jaw.

Authors:  Sebastian Blatt; Maximilian Krüger; Peer W Kämmerer; Daniel G E Thiem; Philipp Matheis; Anne-Katrin Eisenbeiß; Jörg Wiltfang; Bilal Al-Nawas; Hendrik Naujokat
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

4.  Predictive Value of Neutrophil-Lymphocyte Ratio as a Marker in Antiresorptive Agent-Related Osteonecrosis of the Jaw: A Retrospective Analysis.

Authors:  Kazuto Kurohara; Kasumi Shimizu; Taku Murata; Gaku Koizumi; Akira Takigawa; Kokoro Nagata; Kenya Okumura; Naoya Arai
Journal:  Diagnostics (Basel)       Date:  2022-07-29

5.  Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients.

Authors:  Jinpeng Zhuang; Jianing Zu; Changlong Zhou; Yi Sun; Pengyu Kong; Yongbin Jing
Journal:  Dis Markers       Date:  2022-09-14       Impact factor: 3.464

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.